NGM Biopharmaceuticals Inc. is in the midst of a big growth spurt, funded largely by a lucrative deal the privately held drug developer signed with Merck & Co. Inc. last year. The company is adding human resources, with an emphasis on research, planning a move into a new larger headquarters and is on track to have three of its assets in clinical development in 2016.
President Jeff Jonker talked about the firm’s transformation since signing the deal with Merck during an interview at the J
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?